Kisspeptin-10
- Category
- Hormone & Sexual Health
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
Kisspeptin-10 is a synthetic hormone fragment used experimentally to trigger GnRH and LH/FSH release for fertility research, including IVF triggering and testosterone support. GnRH stimulation and IVF triggering have moderate human support, but amenorrhea reversal and anti-cancer claims are speculative. Repeated dosing can desensitize the reproductive axis, and no long-term human safety data exist. It is not FDA-approved, and WADA explicitly listed kisspeptin and its agonist analogues as prohibited at all times in males from 2024.
Read Full recordStudied uses & evidence
Studied uses(8)
GnRH and gonadotropin stimulation
HighMultiple human trials confirm IV KP-10 raises LH and pulse frequency.
Safer IVF oocyte maturation trigger
MediumHuman dose-finding trial used kisspeptin-54, not KP-10, with no head-to-head trigger comparison.
Restoration of reproductive function in hypothalamic amenorrhea
LowSmall studies with KP-54 increased LH pulsatility, but no restored ovulation or fertility shown.
Evidence limits
- Evidence Level
- Phase 1-2
Approximately 50 published studies with human data, including ~18 clinical trials or interventional studies. Most involve healthy volunteers or small patient cohorts (10-50 subjects). The largest IVF trial included 60 women. A 2023 JAMA Network Open RCT (n=32) demonstrated efficacy for HSDD. No Phase 3 trials completed. Evidence is strongest for IVF oocyte maturation triggering and GnRH/LH stimulation.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Hormone-sensitive cancers
HighStimulates GnRH -> LH/FSH -> sex hormone production. May promote hormone-dependent tumor growth.
General cautions
Pregnancy (except controlled IVF use)
AbsoluteDisrupts reproductive hormone signaling.
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
Very short half-life (~4 minutes for KP-10) limits practical clinical utility without continuous infusion
HighTachyphylaxis with continuous/daily dosing — chronic exposure desensitizes GnRH neurons and paradoxically suppresses gonadotropins
HighNo long-term human safety data — all clinical studies involve short-duration exposure
HighSexual dimorphism in response — minimal effect in follicular-phase women, unpredictable in some populations
ModerateNot FDA-approved — no standardized pharmaceutical-grade formulations available outside research settings
HighUnregulated products sold online may have variable purity and quality
HighPotential appetite suppression reported anecdotally; interaction with metabolic pathways not fully characterized
TheoreticalTheoretical concern: chronic HPG axis suppression via desensitization could impair fertility if dosed incorrectly
TheoreticalWADA prohibited in males since 2024 — implications for competitive athletes
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.